ArticleBMJ open2026

ADDRESS-LC: study protocol for a phase 2, triple-blind, randomised, placebo-controlled trial to evaluate the efficacy and safety of bezisterim (NE3107) in adults with long COVID.

Penelope Markham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.